± HEALTH The significant advancements in applying artificial intelligence (AI) to healthcare decision-making, medical…− CLIMATE Abstract Deep learning workloads have experienced rapid growth which has resulted in higher energy consumptio…− EDUCATION Generative artificial intelligence (Gen AI) has taken the academic world by storm. This G.I.F.T.S. paper argu…± HEALTH Spontaneous intracerebral hemorrhage (ICH) is a highly lethal and disabling form of stroke, in which hematoma…− HEALTH Aim To explore the notion of post-humanism and the impact of artificial intelligence (AI) on society, nursing…± EDUCATION Aim To examine nursing academics' perceptions and experiences of artificial intelligence (AI) integration in…+ CRIME Riverbank erosion is a catastrophic geomorphological hazard that poses severe ecological and socio-economic c…+ HEALTH Immunotherapy resistance in lung adenocarcinoma (LUAD) remains a critical clinical challenge, and the mechani…
TruaceTracing the truth around AIMonday, August 17, 2026
Subscribe
Health·G Space·Evidence-backed gain·Published 2026-08-17

Integration of single-cell transcriptomics and genomic mutation analysis identifies an immunotherapy-resistant tumor subcluster and validates ARNTL2 as a malignant driver in lung adenocarcinoma

Abstract: Immunotherapy resistance in lung adenocarcinoma (LUAD) remains a critical clinical challenge, and the mechanisms underlying resistance-associated intratumoral heterogeneity are poorly characterized. We performed single-cell RNA sequencing of LUAD patients receiving neoadjuvant immunotherapy (responders vs. non-responders), integrating inferCNV, GSVA, and differential expression analyses. Cluster-specific genes were validated across seven independent cohorts (TCGA-LUAD, GSE13213, GSE26939, GSE29016, GSE30219, GSE…

TRV-2026-0806Peer-reviewedPermanent record — cite & verify
Integration of single-cell transcriptomics and genomic mutation analysis identifies an immunotherapy-resistant tumor subcluster and validates ARNTL2 as a malignant driver in lung adenocarcinoma

Pleomorphic carcinoma (52166222744) by Atlas of Pulmonary Pathology from USA. CC BY-SA 2.0 · https://creativecommons.org/licenses/by-sa/2.0

The quick read

By August 2026, researchers had used single-cell RNA sequencing of lung adenocarcinoma patients treated with neoadjuvant immunotherapy to map resistance-associated heterogeneity, identifying a malignant Cluster 2 enriched in non-responders with upregulated KRT17, S100A2, and CST6, and built a CoxBoost combined with survivalSVM prognostic model validated across seven independent cohorts.

The work matters because it links a machine-learning-derived risk score to immune infiltration and immunophenoscores and experimentally implicates ARNTL2 as a driver whose knockdown reduces proliferation and invasion, but it remains uncertain whether the C-index of 0.686 and cell-line findings will translate to prospective clinical utility or in vivo therapeutic efficacy.

Main points
  • Single-cell RNA sequencing of LUAD neoadjuvant immunotherapy responders vs non-responders identified resistance-enriched malignant Cluster 2 with hyperproliferative and metabolic reprogramming.
  • Non-responders showed enrichment of epithelial cells, depletion of cytotoxic T/NK cells, and elevated copy number variation burden versus responders (p < 0.0001).
  • Cluster genes KRT17, S100A2, and CST6 showed tumor-specific overexpression, adverse prognostic value, and genomic amplification across seven cohorts including TCGA-LUAD.
  • ARNTL2 was an independent prognostic factor (HR: 2.07-4.64) correlated with risk score (r = 0.69) and validated as oncogenic driver in vitro.
Gain

A CoxBoost + survivalSVM prognostic model built from resistance-associated cluster genes achieved C-index 0.686 and stratified LUAD patients with HR 2.54-10.51, with low-risk patients showing greater immune infiltration and ARNTL2 knockdown suppressing proliferation and invasion in A549 and H1299 cells.

The rundown

Researchers performed single-cell RNA sequencing on LUAD patients receiving neoadjuvant immunotherapy, integrating inferCNV, GSVA, and differential expression to compare responders and non-responders, and validated cluster-specific genes across TCGA-LUAD and six GEO cohorts.

A multi-algorithm machine learning framework selected CoxBoost + survivalSVM as optimal, with immune characterization via TCIA scoring, seven infiltration algorithms, and ESTIMATE, and functional validation of ARNTL2 by CCK-8 and Transwell assays in A549 and H1299 cells.

Sources

Reader signal

How should this claim be treated?

The debate